Sitagliptin Tablets
utilized to target blood glucose levels in type 2 diabetes mellitus to support metabolic control.
Strengths: 50 · 100mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Januvia
- Therapeutic class
Dipeptidyl Peptidase-4 (DPP-4) Inhibitor
- Pharmacological class
Dipeptidyl Peptidase-4 Inhibitor
- Contraindications
hypersensitivity to sitagliptin
- Precautions and warnings
monitor for signs of pancreatitis; use with caution in renal impairment
- Minor side effects
nasopharyngitis; upper respiratory tract infection; headache
- Moderate side effects
hypoglycaemia
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Merck Sharp & Dohme
- Onset Time
1–2 weeks
- Duration
24 hours
- Storage instructions
Store at room temperature away from high humidity.
- Drug interactions
digoxin
- Age restrictions
Not recommended for those under 18 years.
Serious side effects
acute pancreatitis — requires immediate medical attention; anaphylaxis — requires immediate medical attention
Patient summary
utilized to target blood glucose levels in type 2 diabetes mellitus to support metabolic control.
Mechanism of action
It serves as a selective inhibitor of the DPP-4 enzyme, which increases the levels of active incretin hormones. This mechanism encourages the body to release larger amounts of insulin and decrease glucagon production when necessary.
Pregnancy and breastfeeding
Pregnancy: Safety not established; use if potential benefit justifies risk. Breastfeeding: Consult a physician.
Sitagliptin Tablets
utilized to target blood glucose levels in type 2 diabetes mellitus to support metabolic control.
Editorial Notes
- Active ingredient(s): Sitagliptin
- Listed indication(s): Type 2 Diabetes Mellitus
Usually available as
- 30 tablets - 50 mg1464-50-mg-17467
- 30 tablets - 100 mg1464-100-mg-17473